Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 412

1.

Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S.

Ann Oncol. 2019 May;30(5):863-870. doi: 10.1093/annonc/mdy474. Epub 2019 Dec 4. No abstract available.

PMID:
31987360
2.

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.

van Veggel B, Madeira R Santos JFV, Hashemi SMS, Paats MS, Monkhorst K, Heideman DAM, Groves M, Radonic T, Smit EF, Schuuring E, van der Wekken AJ, de Langen AJ.

Lung Cancer. 2020 Mar;141:9-13. doi: 10.1016/j.lungcan.2019.12.013. Epub 2019 Dec 20.

PMID:
31926441
3.

Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.

Smit HJM, Aerts J, van den Heuvel M, Hiltermann TJN, Bahce I, Smit EF, Dingemans AC, Hendriks LE, Stigt JA, Schramel FMNH, van Tinteren H, Groen HJM; all participants of NVALT Immunotherapy Register (see addendum).

Lung Cancer. 2020 Feb;140:107-112. doi: 10.1016/j.lungcan.2019.12.011. Epub 2019 Dec 28.

PMID:
31911323
4.

Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis.

Ten Berge DMHJ, Hurkmans DP, den Besten I, Kloover JS, Mathijssen RHJ, Debets RJEMA, Smit EF, Aerts JGJV.

ERJ Open Res. 2019 Dec 16;5(4). pii: 00179-2019. doi: 10.1183/23120541.00179-2019. eCollection 2019 Oct.

5.

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, Camidge DR.

J Thorac Oncol. 2019 Nov 19. pii: S1556-0864(19)33645-7. doi: 10.1016/j.jtho.2019.11.004. [Epub ahead of print]

6.

Correction: Clonality analysis of pulmonary tumors by genome-wide copy number profiling.

Vincenten JPL, van Essen HF, Lissenberg-Witte BI, Bulkmans NWJ, Krijgsman O, Sie D, Eijk PP, Smit EF, Ylstra B, Thunnissen E.

PLoS One. 2019 Nov 19;14(11):e0225733. doi: 10.1371/journal.pone.0225733. eCollection 2019.

7.

Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study.

Witlox WJA, Ramaekers BLT, Joore MA, Dingemans AC, Praag J, Belderbos J, Tissing-Tan C, Herder G, Haitjema T, Ubbels JF, Lagerwaard J, El Sharouni SY, Stigt JA, Smit EF, van Tinteren H, van der Noort V, Groen HJM, De Ruysscher DKM.

Radiother Oncol. 2019 Nov 13;144:65-71. doi: 10.1016/j.radonc.2019.10.016. [Epub ahead of print]

PMID:
31733490
8.

DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.

Hermans BCM, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJM, Smit EF, Damhuis RA, van den Broek EC; PALGA-group, Ruland A, Speel EJM, Dingemans AMC.

Lung Cancer. 2019 Dec;138:102-108. doi: 10.1016/j.lungcan.2019.10.010. Epub 2019 Oct 13.

PMID:
31678831
9.

Pan-cancer whole-genome analyses of metastatic solid tumours.

Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, Roepman P, Voda M, Bloemendal HJ, Tjan-Heijnen VCG, van Herpen CML, Labots M, Witteveen PO, Smit EF, Sleijfer S, Voest EE, Cuppen E.

Nature. 2019 Nov;575(7781):210-216. doi: 10.1038/s41586-019-1689-y. Epub 2019 Oct 23.

10.

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.

Thunnissen E, Lissenberg-Witte BI, van den Heuvel MM, Monkhorst K, Skov BG, Sørensen JB, Mellemgaard A, Dingemans AMC, Speel EJM, de Langen AJ, Hashemi SMS, Bahce I, van der Drift MA, Looijen-Salamon MG, Gosney J, Postmus PE, Samii SMS, Duplaquet F, Weynand B, Durando X, Penault-Llorca F, Finn S, Grady AO, Oz B, Akyurek N, Buettner R, Wolf J, Bubendorf L, Duin S, Marondel I, Heukamp LC, Timens W, Schuuring EMD, Pauwels P, Smit EF.

Lung Cancer. 2019 Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023. Epub 2019 Oct 3.

PMID:
31630043
11.

Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.

Okonska A, Bühler S, Rao V, Ronner M, Blijlevens M, van der Meulen-Muileman IH, de Menezes RX, Wipplinger M, Oehl K, Smit EF, Weder W, Stahel RA, Penengo L, van Beusechem VW, Felley-Bosco E.

Mol Cancer Ther. 2020 Feb;19(2):552-563. doi: 10.1158/1535-7163.MCT-19-0356. Epub 2019 Oct 16.

12.

Clonality analysis of pulmonary tumors by genome-wide copy number profiling.

Vincenten JPL, van Essen HF, Lissenberg-Witte BI, Bulkmans NWJ, Krijgsman O, Sie D, Eijk PP, Smit EF, Ylstra B, Thunnissen E.

PLoS One. 2019 Oct 16;14(10):e0223827. doi: 10.1371/journal.pone.0223827. eCollection 2019. Erratum in: PLoS One. 2019 Nov 19;14(11):e0225733.

13.

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE.

Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30.

PMID:
31570881
14.

Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S.

J Thorac Oncol. 2019 Dec;14(12):2109-2119. doi: 10.1016/j.jtho.2019.07.025. Epub 2019 Aug 6.

PMID:
31398540
15.

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.

Groen HJM, van der Heijden EHFM, Klinkenberg TJ, Biesma B, Aerts J, Verhagen A, Kloosterziel C, Pieterman R, van den Borne B, Smit HJM, Hoekstra O, Schramel FMNH, van der Noort V, van Tinteren H, Smit EF, Dingemans AC; NVALT Study Group, the Netherlands.

Br J Cancer. 2019 Aug;121(5):372-377. doi: 10.1038/s41416-019-0533-3. Epub 2019 Jul 24.

PMID:
31337877
16.

The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.

Degens JHRJ, Sanders KJC, de Jong EEC, Groen HJM, Smit EF, Aerts JG, Schols AMWJ, Dingemans AC.

Lung Cancer. 2019 Jul;133:130-135. doi: 10.1016/j.lungcan.2019.05.021. Epub 2019 May 20.

17.

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J.

J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9.

PMID:
30978502
18.

Pembrolizumab for all PD-L1-positive NSCLC.

Smit EF, de Langen AJ.

Lancet. 2019 May 4;393(10183):1776-1778. doi: 10.1016/S0140-6736(18)32559-5. Epub 2019 Apr 4. No abstract available.

PMID:
30955976
19.

Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions.

Hummelink K, Muller M, Linders TC, van der Noort V, Nederlof PM, Baas P, Burgers S, Smit EF, Meijer GA, van den Heuvel MM, van den Broek D, Monkhorst K.

ERJ Open Res. 2019 Mar 25;5(1). pii: 00016-2019. doi: 10.1183/23120541.00016-2019. eCollection 2019 Feb.

20.

Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: which groups specifically benefit? Secondary analyses of a randomized controlled trial.

Jansen F, Lissenberg-Witte BI, Krebber AMH, Cuijpers P, de Bree R, Becker-Commissaris A, Smit EF, van Straten A, Eeckhout GM, Beekman ATF, Leemans CR, Verdonck-de Leeuw IM.

Support Care Cancer. 2019 Dec;27(12):4543-4553. doi: 10.1007/s00520-019-04714-3. Epub 2019 Mar 27.

21.

How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.

Peters S, Reck M, Smit EF, Mok T, Hellmann MD.

Ann Oncol. 2019 Jun 1;30(6):884-896. doi: 10.1093/annonc/mdz109.

PMID:
30912805
22.

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.

Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Delli Pizzi A, Lalezari F, Lambregts DMJ, Rohaan MW, Parmar C, Rozeman EA, Hartemink KJ, Swanton C, Haanen JBAG, Blank CU, Smit EF, Beets-Tan RGH, Aerts HJWL.

Ann Oncol. 2019 Jun 1;30(6):998-1004. doi: 10.1093/annonc/mdz108.

23.

Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).

Hermans BCM, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJM, Smit EF, Damhuis RA, van den Broek EC, Stallinga CM, Roemen GM, Speel EJM, Dingemans AC; PALGA-group.

Lung Cancer. 2019 Apr;130:179-186. doi: 10.1016/j.lungcan.2019.02.022. Epub 2019 Feb 21.

PMID:
30885341
24.

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S.

J Thorac Oncol. 2019 Jun;14(6):1086-1094. doi: 10.1016/j.jtho.2019.02.017. Epub 2019 Feb 27.

PMID:
30825613
25.

Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients.

Kolinger GD, Vállez García D, Kramer GM, Frings V, Smit EF, de Langen AJ, Dierckx RAJO, Hoekstra OS, Boellaard R.

EJNMMI Res. 2019 Feb 7;9(1):14. doi: 10.1186/s13550-019-0481-1.

26.

Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics.

Cysouw MCF, Golla SVS, Frings V, Smit EF, Hoekstra OS, Kramer GM, Boellaard R; QuIC-ConCePT Consortium.

EJNMMI Res. 2019 Feb 4;9(1):12. doi: 10.1186/s13550-019-0483-z.

27.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S.

Ann Oncol. 2019 May 1;30(5):863-870. doi: 10.1093/annonc/mdy474. No abstract available.

PMID:
30715168
28.

Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.

Böttger F, Schaaij-Visser TB, de Reus I, Piersma SR, Pham TV, Nagel R, Brakenhoff RH, Thunnissen E, Smit EF, Jimenez CR.

J Proteomics. 2019 Mar 30;196:106-119. doi: 10.1016/j.jprot.2019.01.018. Epub 2019 Jan 30.

PMID:
30710758
29.

High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome.

Blijlevens M, van der Meulen-Muileman IH, de Menezes RX, Smit EF, van Beusechem VW.

Oncogene. 2019 May;38(21):4142-4153. doi: 10.1038/s41388-019-0711-z. Epub 2019 Jan 31.

PMID:
30705407
30.

Long-term expanding human airway organoids for disease modeling.

Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, Weeber F, Huelsz-Prince G, Iakobachvili N, Amatngalim GD, de Ligt J, van Hoeck A, Proost N, Viveen MC, Lyubimova A, Teeven L, Derakhshan S, Korving J, Begthel H, Dekkers JF, Kumawat K, Ramos E, van Oosterhout MF, Offerhaus GJ, Wiener DJ, Olimpio EP, Dijkstra KK, Smit EF, van der Linden M, Jaksani S, van de Ven M, Jonkers J, Rios AC, Voest EE, van Moorsel CH, van der Ent CK, Cuppen E, van Oudenaarden A, Coenjaerts FE, Meyaard L, Bont LJ, Peters PJ, Tans SJ, van Zon JS, Boj SF, Vries RG, Beekman JM, Clevers H.

EMBO J. 2019 Feb 15;38(4). pii: e100300. doi: 10.15252/embj.2018100300. Epub 2019 Jan 14.

31.

Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.

de Goeje PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, Groen HJM, Smit EF, Dingemans AC, Kunert A, Hendriks RW, Aerts JGJV.

Clin Cancer Res. 2019 Apr 1;25(7):2219-2227. doi: 10.1158/1078-0432.CCR-18-2243. Epub 2019 Jan 14.

PMID:
30642911
32.

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.

Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, Boellaard R, Du S, Hayes W, Smith R, Windhorst AD, Hendrikse NH, Poot A, Vugts DJ, Thunnissen E, Morin P, Lipovsek D, Donnelly DJ, Bonacorsi SJ, Velasquez LM, de Gruijl TD, Smit EF, de Langen AJ.

Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y.

33.

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.

Fassunke J, Müller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Heimsoeth A, Dahmen I, Fischer RN, Scheffler M, Ihle MA, Priesner V, Scheel AH, Wagener S, Kron A, Frank K, Garbert K, Persigehl T, Püsken M, Haneder S, Schaaf B, Rodermann E, Engel-Riedel W, Felip E, Smit EF, Merkelbach-Bruse S, Reinhardt HC, Kast SM, Wolf J, Rauh D, Büttner R, Sos ML.

Nat Commun. 2018 Nov 7;9(1):4655. doi: 10.1038/s41467-018-07078-0.

34.

Variability and Repeatability of Quantitative Uptake Metrics in 18F-FDG PET/CT of Non-Small Cell Lung Cancer: Impact of Segmentation Method, Uptake Interval, and Reconstruction Protocol.

Zhuang M, García DV, Kramer GM, Frings V, Smit EF, Dierckx R, Hoekstra OS, Boellaard R.

J Nucl Med. 2019 May;60(5):600-607. doi: 10.2967/jnumed.118.216028. Epub 2018 Nov 2.

PMID:
30389824
35.

Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.

Wijn DH, Groeneveld GH, Vollaard AM, Muller M, Wallinga J, Gelderblom H, Smit EF.

Eur J Cancer. 2018 Nov;104:182-187. doi: 10.1016/j.ejca.2018.09.012. Epub 2018 Oct 24.

PMID:
30368069
36.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275. No abstract available. Erratum in: Ann Oncol. 2019 May 1;30(5):863-870. Ann Oncol. 2019 May;30(5):863-870.

37.

Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.

van Veggel B, de Langen AJ, Hashemi S, Monkhorst K, Rosenberg EH, Heideman DAM, Radonic T, Smit EF.

Lung Cancer. 2018 Oct;124:130-134. doi: 10.1016/j.lungcan.2018.07.030. Epub 2018 Jul 30.

38.

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S, van Rooij N, van Leerdam ME, Depla A, Smit EF, Hartemink KJ, de Groot R, Wolkers MC, Sachs N, Snaebjornsson P, Monkhorst K, Haanen J, Clevers H, Schumacher TN, Voest EE.

Cell. 2018 Sep 6;174(6):1586-1598.e12. doi: 10.1016/j.cell.2018.07.009. Epub 2018 Aug 9.

39.

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.

de Langen AJ, Jebbink M, Hashemi SMS, Kuiper JL, de Bruin-Visser J, Monkhorst K, Thunnissen E, Smit EF.

Br J Cancer. 2018 Aug;119(5):558-564. doi: 10.1038/s41416-018-0194-7. Epub 2018 Jul 31.

40.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N.

Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196. Review.

41.

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N.

Clin Lung Cancer. 2018 Jul;19(4):331-339. doi: 10.1016/j.cllc.2018.03.014. Epub 2018 Mar 21. Review.

42.

The efficacy of Life Review Therapy combined with Memory Specificity Training (LRT-MST) targeting cancer patients in palliative care: A randomized controlled trial.

Kleijn G, Lissenberg-Witte BI, Bohlmeijer ET, Steunenberg B, Knipscheer-Kuijpers K, Willemsen V, Becker A, Smit EF, Eeltink CM, Bruynzeel AME, van der Vorst M, de Bree R, Leemans CR, van den Brekel MWM, Cuijpers P, Verdonck-de Leeuw IM.

PLoS One. 2018 May 15;13(5):e0197277. doi: 10.1371/journal.pone.0197277. eCollection 2018.

43.

Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.

Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M.

Cancer Chemother Pharmacol. 2018 Jul;82(1):77-86. doi: 10.1007/s00280-018-3560-5. Epub 2018 May 2.

PMID:
29721850
44.

Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.

van Veggel B, de Langen AJ, Hashemi SMS, Monkhorst K, Heideman DAM, Thunnissen E, Smit EF.

J Thorac Oncol. 2018 Aug;13(8):1222-1226. doi: 10.1016/j.jtho.2018.04.012. Epub 2018 Apr 24.

45.

Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor.

Iqbal R, Kramer GM, Frings V, Smit EF, Hoekstra OS, Boellaard R; QuIC-ConCePT Consortium.

EJNMMI Res. 2018 Mar 27;8(1):22. doi: 10.1186/s13550-018-0376-6.

46.

Prophylactic cranial irradiation for stage IV small cell lung cancer, live longer or reduce morbidity of brain metastases?

Postmus PE, Smit EF.

J Thorac Dis. 2017 Oct;9(10):3572-3575. doi: 10.21037/jtd.2017.09.50. No abstract available.

47.

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB.

J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.

48.

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.

Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S; ETOP Lungscape Consortium.

Ann Oncol. 2018 Jan 1;29(1):200-208. doi: 10.1093/annonc/mdx629.

49.

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM.

Lung Cancer. 2017 Nov;113:51-58. doi: 10.1016/j.lungcan.2017.08.014. Epub 2017 Aug 31.

50.

PD-L1 IHC in NSCLC with a global and methodological perspective.

Thunnissen E, de Langen AJ, Smit EF.

Lung Cancer. 2017 Nov;113:102-105. doi: 10.1016/j.lungcan.2017.09.010. Epub 2017 Sep 18. Review.

Supplemental Content

Support Center